Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational study.

[1]  D. Lynch,et al.  FEV(1)/FEV(6) to diagnose airflow obstruction. Comparisons with computed tomography and morbidity indices. , 2014, Annals of the American Thoracic Society.

[2]  P. Calverley,et al.  Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. , 2013, The Lancet. Respiratory medicine.

[3]  E. Regan,et al.  Automated Telecommunication to Obtain Longitudinal Follow-up in a Multicenter Cross-sectional COPD Study , 2012, COPD.

[4]  Susan Murray,et al.  Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease , 2012, Thorax.

[5]  E. Regan,et al.  Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. , 2011, American journal of respiratory and critical care medicine.

[6]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[7]  W. MacNee,et al.  Airway dimensions in COPD: relationships with clinical variables. , 2010, Respiratory medicine.

[8]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[9]  Anand A. Dalal,et al.  Burden of COPD, asthma, and concomitant COPD and asthma among adults: racial disparities in a medicaid population. , 2009, Chest.

[10]  Yasutaka Nakano,et al.  Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[11]  E. Burchard,et al.  Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  LT Sarah E. Broski,et al.  Paradoxical Response to Levalbuterol , 2008, The Journal of the American Osteopathic Association.

[13]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[14]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[15]  E. Burchard,et al.  Ethnic-Specific Differences in Bronchodilator Responsiveness Among African Americans, Puerto Ricans, and Mexicans with Asthma , 2007, The Journal of asthma : official journal of the Association for the Care of Asthma.

[16]  W. Bailey,et al.  COPD: racial disparities in susceptibility, treatment, and outcomes. , 2006, Clinics in chest medicine.

[17]  N. Nagajothi,et al.  Paradoxical Bronchospasm: A Potentially Life Threatening Adverse Effect of Albuterol , 2006, Southern medical journal.

[18]  Linda M. Spooner,et al.  Paradoxical Bronchoconstriction with Albuterol Administered by Metered-Dose Inhaler and Nebulizer Solution , 2005, The Annals of pharmacotherapy.

[19]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[20]  Jan Stolk,et al.  Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. , 2004, American journal of respiratory and critical care medicine.

[21]  W. Bailey,et al.  Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. , 2004, Respiratory medicine.

[22]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[23]  H. Bauchner,et al.  Physicians , 2001, BMJ : British Medical Journal.

[24]  L. Antonicelli,et al.  Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. , 1996, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[25]  B. Lipworth,et al.  Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients , 1995, The Lancet.

[26]  P. Howarth,et al.  Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline. , 1993, The American review of respiratory disease.

[27]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[28]  Nicklas Ra.  Paradoxical bronchospasm associated with the use of inhaled beta agonists , 1990 .

[29]  C K Wells,et al.  Evaluation of clinical methods for rating dyspnea. , 1988, Chest.

[30]  C. O’Callaghan,et al.  PARADOXICAL DETERIORATION IN LUNG FUNCTION AFTER NEBULISED SALBUTAMOL IN WHEEZY INFANTS , 1986, The Lancet.

[31]  R. C. Kory,et al.  Criteria for the assessment of reversibility in airways obstruction. Report of the Committee on Emphysema American College of Chest Physicians. , 1974, Chest.

[32]  E. Bateman,et al.  International Journal of Copd Dovepress Lack of Paradoxical Bronchoconstriction after Administration of Tiotropium via Respimat ® Soft Mist™ Inhaler in Copd , 2022 .

[33]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[34]  M. Dahmer,et al.  Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. , 2006, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[35]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[36]  S. Spector,et al.  Paradoxical bronchospasm after use of inhalation aerosols: a review of the literature. , 1991, The Journal of asthma : official journal of the Association for the Care of Asthma.

[37]  R. Nicklas.  Paradoxical bronchospasm associated with the use of inhaled beta agonists. , 1990, The Journal of allergy and clinical immunology.